Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pacira Pharm Inc
(NQ:
PCRX
)
26.25
+0.15 (+0.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
448,972
Open
25.98
Bid (Size)
26.25 (1)
Ask (Size)
28.26 (1)
Prev. Close
26.10
Today's Range
25.91 - 26.34
52wk Range
25.76 - 48.60
Shares Outstanding
44,454,792
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
April 09, 2024
Via
Benzinga
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Performance
YTD
-17.97%
-17.97%
1 Month
-10.93%
-10.93%
3 Month
-17.27%
-17.27%
6 Month
-8.50%
-8.50%
1 Year
-42.18%
-42.18%
More News
Read More
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
March 28, 2024
Via
Chartmill
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
March 20, 2024
Via
AB Newswire
Topics
Death
Exposures
Death
Navigating 4 Analyst Ratings For Pacira BioSciences
March 01, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Preview: Pacira BioSciences's Earnings
February 28, 2024
Via
Benzinga
NASDAQ:PCRX is an undervalued gem with solid fundamentals.
January 19, 2024
Via
Chartmill
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
March 13, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
March 06, 2024
From
Pacira BioSciences
Via
GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
March 01, 2024
Via
Chartmill
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024
From
Pacira BioSciences
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
December 20, 2023
Via
Benzinga
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
February 22, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
February 15, 2024
From
Pacira BioSciences
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
February 09, 2024
Via
Chartmill
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
February 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
January 04, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
December 21, 2023
From
Pacira BioSciences
Via
GlobeNewswire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
December 20, 2023
Via
Chartmill
Investors should take notice of NASDAQ:PCRX—it offers a great deal for the fundamentals it presents.
November 29, 2023
Via
Chartmill
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications
November 10, 2023
From
Pacira BioSciences
Via
GlobeNewswire
For those who appreciate value investing, NASDAQ:PCRX is a compelling option with its solid fundamentals.
November 08, 2023
Via
Chartmill
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.